MicroRNA profiling in lung cancer reveals new molecular markers for diagnosis

Acta Cytologica

Volumn 56, Issue 6, 2012, Pages 645-654

  Solomides, Charalambos C ^a   Evans, Barry J ^a   Navenot, Jean Marc ^a   Vadigepalli, Rajanikanth ^a   Peiper, Stephen C ^a   Wang, Zi Xuan ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Adenocarcinoma; Algorithm; Diagnosis; Lung cancer; Microarray; MicroRNA; Quantitative real time PCR; Squamous cell carcinoma

Indexed keywords

MICRORNA; MICRORNA 205; MICRORNA 26B; MICRORNA 451; MICRORNA 486 5P; MOLECULAR MARKER; UNCLASSIFIED DRUG;

ALGORITHM; CANCER CLASSIFICATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MICROARRAY ANALYSIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; TISSUE SECTION; TUMOR DIFFERENTIATION;

EID: 84870723323     PISSN: 00015547     EISSN: None     Source Type: Journal    
DOI: 10.1159/000343473     Document Type: Review

References (38)

1. WHO: Cancer. 2011. http://www.who.int/mediacentre/factsheets/fs297/en/ index. html.
2. Travis WD, Brambilla E, Noguchi M, et al: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-285.
3. Kenfield SA, Wei EK, Stampfer MJ, et al: Comparison of aspects of smoking among the four histological types of lung cancer. Tob Control 2008; 17: 198-204.
4. Neal JW: Histology matters: individualizing treatment in non-small cell lung cancer. Oncologist 2010; 15: 3-5.
5. Field RW, Smith BJ, Platz CE, et al: Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. J Natl Cancer Inst 2004; 96: 1105-1107. (Pubitemid 39172413)
6. Stang A, Pohlabeln H, Muller KM, et al: Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. Lung Cancer 2006; 52: 29-36. (Pubitemid 43340196)
7. Cataluna JJ, Perpina M, Greses JV, et al: Cell type accuracy of bronchial biopsy specimens in primary lung cancer. Chest 1996; 109: 1199-1203. (Pubitemid 26145656)
8. Edwards SL, Roberts C, McKean ME, et al: Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category. J Clin Pathol 2000; 53: 537-540. (Pubitemid 30432112)
9. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
10. Kargi A, Gurel D, Tuna B: The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol 2007; 15: 415-420. (Pubitemid 350307847)
11. Mukhopadhyay S, Katzenstein AL: Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 2011; 35: 15-25.
12. Rossi G, Pelosi G, Graziano P, et al: A reevaluation of the clinical significance of histological subtyping of non-small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments. Int J Surg Pathol 2009; 17: 206-218.
13. Tomankova T, Petrek M, Kriegova E: Involvement of microRNAs in physiological and pathological processes in the lung. Respir Res 2010; 11: 159.
14. Hatley ME, Patrick DM, Garcia MR, et al: Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 2010; 18: 282-293.
15. Saito M, Schetter AJ, Mollerup S, et al: The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res 2011; 17: 1875-1882.
16. Seike M, Goto A, Okano T, et al: MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci USA 2009; 106: 12085-12090.
17. Zhang JG, Wang JJ, Zhao F, et al: Micro-RNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta 2010; 411: 846-852.
18. Bishop JA, Benjamin H, Cholakh H, et al: Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res 2010; 16: 610-619.
19. Lebanony D, Benjamin H, Gilad S, et al: Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 2009; 27: 2030-2037.
20. Del Vescovo V, Cantaloni C, Cucino A, et al: miR-205 expression levels in nonsmall cell lung cancer do not always distinguish adenocarcinomas from squamous cell carcinomas. Am J Surg Pathol 2011; 35: 268-275.
21. Pradervand S, Weber J, Thomas J, et al: Impact of normalization on miRNA microarray expression profiling. RNA 2009; 15: 493-501.
22. Bolstad BM, Irizarry RA, Astrand M, et al: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003; 19: 185-193. (Pubitemid 36181903)
23. Johnson WE, Li C, Rabinovic A: Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007; 8: 118-127. (Pubitemid 44906106)
24. Saeed AI, Sharov V, White J, et al: TM4: a free, open-source system for microarray data management and analysis. Biotechniques 2003; 34: 374-378. (Pubitemid 36184095)
25. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995; 57: 289-300.
26. Roa W, Brunet B, Guo L, et al: Identification of a new microRNA expression profile as a potential cancer screening tool. Clin Invest Med 2010; 33:E124.
27. Volinia S, Calin GA, Liu CG, et al: A micro-RNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-2261. (Pubitemid 43271657)
28. Zhu S, Wu H, Wu F, et al: MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 2008; 18: 350-359. (Pubitemid 351333899)
29. Gao W, Shen H, Liu L, et al: MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J Cancer Res Clin Oncol 2011; 137: 557-566.
30. Tan X, Qin W, Zhang L, et al: A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin Cancer Res 2011; 17: 6802-6811.
31. Garzon R, Marcucci G, Croce CM: Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9: 775-789.
32. Wang R, Wang ZX, Yang JS, et al: Micro-RNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene 2011; 30: 2644-2658.
33. Wu N, Zhao X, Liu M, et al: Role of micro-RNA-26b in glioma development and its mediated regulation on EphA2. PLoS One 2011; 6:e16264.
34. Navon R, Wang H, Steinfeld I, et al: Novel rank-based statistical methods reveal microRNAs with differential expression in multiple cancer types. PLoS One 2009; 4:e8003.
35. Greene SB, Herschkowitz JI, Rosen JM: The ups and downs of miR-205: identifying the roles of miR-205 in mammary gland development and breast cancer. RNA Biol 2010; 7: 300-304.
36. Yu J, Ryan DG, Getsios S, et al: Micro-RNA-184 antagonizes microRNA-205 to maintain SHIP2 levels in epithelia. Proc Natl Acad Sci USA 2008; 105: 19300-19305.
37. Fassina A, Cappellesso R, Fassan M: Classification of non-small cell lung carcinoma in transthoracic needle specimens using microRNA expression profiling. Chest 2011; 140: 1305-1311.
38. Gilad S, Lithwick-Yanai G, Barshack I, et al: Classification of the four main types of lung cancer using a microRNA-based diagnostic assay. J Mol Diagn 2012; 14: 510-517.